Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1932 - High chemopreventive and therapeutic efficacy of Id1 Inhibition in KRAS-mutant (KM) adenocarcinoma (AD) non-small cell lung cancer (NSCLC)


11 Sep 2017


Poster display session


Cancer Biology;  Thoracic Malignancies


Marta Roman Moreno


Annals of Oncology (2017) 28 (suppl_5): v1-v21. 10.1093/annonc/mdx361


M. Roman Moreno1, S. Vicent2, I. Lopez2, I. Baraibar Argota1, E. Fraile2, I. Gil Bazo1

Author affiliations

  • 1 Medical Oncology, Clinica Universitaria de Navarra, 31008 - Pamplona/ES
  • 2 Tumores Solidos Y Biomarcadores, CENTRO DE INVESTIGACION MEDICA APLICADA (CIMA), 31008 - PAMPLONA/ES


Abstract 1932


Id1 is an independent prognostic factor in NSCLC-AD. Id1 silencing impairs cell viability and migration of NSCLC-AD cell lines. KRAS is the most frequently mutant gene in NSCLC with no specific therapies clinically available. Here we evaluate Id1 as a potential chemopreventive and therapeutic target in a humanized mouse model of KM NSCLC-AD.


Several human lung AD cell lines with known mutations (H1792-604, H2009, H358, H1568, H1437, H1703 and H2126) were selected for Id1 silencing using inducible short hairpin RNA (shRNA). Humanized AD xenograft mouse models were generated by subcutaneous injection of H1792-604 and H2009 cell lines (Id1 silenced or Id1 wild type) in flanks of immunodeficient mice. Id1 silencing was activated at the time of tumor cell inoculation (chemoprevention assay) or once the tumors were established (therapeutic assay).


Id1 inhibition was achieved in all selected cell lines compared to their controls. In vivo, in the chemoprevention assay we observed a significant decrease in tumor volume in mice injected with Id1 silenced H1792-604 cells (60% ± 32.39) compared to the control group (356.29% ± 115.32) (p 


These findings encourage further evaluation of Id1 as a potential therapeutic target in KM NSCLC-AD patients.

Clinical trial identification

Legal entity responsible for the study

Clínica Universidad de Navarra


Clínica Universidad de Navarra


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.